BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/26/2023 8:08:23 AM | Browse: 131 | Download: 176
 |
Received |
|
2023-02-03 02:26 |
|
Peer-Review Started |
|
2023-02-03 02:30 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-02-21 06:38 |
|
Revised |
|
2023-03-03 20:39 |
|
Second Decision |
|
2023-05-08 03:12 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-05-08 07:56 |
|
Articles in Press |
|
2023-05-08 07:56 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2023-05-02 18:44 |
|
Typeset the Manuscript |
|
2023-05-26 01:07 |
|
Publish the Manuscript Online |
|
2023-05-26 08:08 |
| ISSN |
2218-6255 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Minireviews |
| Article Title |
Monoclonal antibody for COVID-19: Unveiling the recipe of a new cocktail
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jyoti Bajpai, Surya Kant, Ajay Kumar Verma and Akshyaya Pradhan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jyoti Bajpai, MD, Assistant Professor, Doctor, Department of Respiratory Medicine, King George’s Medical University, E 1204 Shalimar Gallant Mahanagar , Lucknow 226003, India. jyotibajpai33@gmail.com |
| Key Words |
SARS-CoV-2; Mild COVID-19; Antibodies; Risk factors |
| Core Tip |
The coronavirus disease 2019 (COVID-19) pandemic is a severe public health emergency that necessitates the rapid development of novel medicines and viral detection technologies. Monoclonal antibodies against the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have become an important target for the creation of therapeutic antibodies. The use of antibody cocktails is anticipated to be a key component of an efficient COVID-19 treatment plan because SARS-CoV-2 has a high mutation rate, particularly when subjected to the selection pressure of aggressively applied preventive vaccinations and neutralising antibodies. |
| Publish Date |
2023-05-26 08:08 |
| Citation |
Bajpai J, Kant S, Verma AK, Pradhan A. Monoclonal antibody for COVID-19: Unveiling the recipe of a new cocktail. World J Respirol 2023; 12(1): 1-9 |
| URL |
https://www.wjgnet.com/2218-6255/full/v12/i1/1.htm |
| DOI |
https://dx.doi.org/10.5320/wjr.v12.i1.1 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
